Ocular Therapeutix™ Reports Second Quarter 2026 Financial Results and Business Highlights
Globe Newswire•03/08/2026•07:00 ET
0
Whiz Insights
Ocular’s AXPAXLI(TM) wet AMD NDA submission on track for Q4 2026 following positive Type C Meeting with the U.S. FDA in May 2026
FDA Type C Meeting Minutes Formalize SOL-1 Trial with Confirmatory Evidence as Sufficient to Support Submission of AXPAXLI NDA in wet AMD
Get started
Create a free account to read the full story.